Copyright: ©Author(s) 2026.
World J Gastrointest Pharmacol Ther. Jun 5, 2026; 17(2): 114876
Published online Jun 5, 2026. doi: 10.4292/wjgpt.v17.i2.114876
Published online Jun 5, 2026. doi: 10.4292/wjgpt.v17.i2.114876
Table 3 Evolution of hepatic steatosis, mean ± SE
| M0 | M36 | P value M0 vs M36 | ||
| CAP med (dB/m) | Chx: Yes | 300.77 ± 47.42 | 314.17 ± 44.70 | 0.013 |
| Chx: No | 325.06 ± 41.74 | 296.36 ± 56.51 | < 0.001 | |
| Graisse hepatique/IRM (%) | Chx: Yes | 14.22 ± 8.64 | 15.98 ± 7.93 | < 0.001 |
| Chx: No | 18.55 ± 8.57 | 13.88 ± 8.12 | < 0.001 | |
- Citation: Amalou K, Belal N, Tibouk A, Ghedada Y, Rekab R, Fadel S, Debzi N, Bousloub A. Effect of cholecystectomy on liver fat and fibrosis in metabolic dysfunction-associated steatotic liver disease patients. World J Gastrointest Pharmacol Ther 2026; 17(2): 114876
- URL: https://www.wjgnet.com/2150-5349/full/v17/i2/114876.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v17.i2.114876